Bain Capital, a US private equity firm, has acquired Mitsubishi Chemical Group’s pharmaceutical unit, Mitsubishi Tanabe Pharma, in a deal valued at approximately Y510bn ($3.3bn).

Through the acquisition, Bain Capital intends to enhance its growth potential through increased R&D investment and align its management policies with long-term strategic goals. The deal also allows Mitsubishi Chemical Group to strengthen its financial position, reduce debt, and focus on its core chemicals business. The deal is expected to close in Q3 2025.